Edgewise Therapeutics, Inc.
- Open
- 42.61
- Day high
- 43.94
- Day low
- 40.76
- Prev close
- 42.25
- Volume
- 862K
- Mkt cap
- $4.6B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 10.2
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$9.8M over the last 3 months (0 open-market buys, 21 sales)
- 🏛Institutions accumulating (13F)
Edgewise Therapeutics, Inc. (EWTX) is a Healthcare company listed on NASDAQ. The stock is up 180% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 21 sales (SEC Form 4). Drillr has 1 published research article covering EWTX.
Edgewise Therapeutics, Inc. (EWTX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 7 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
EWTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.47 | $-0.53 | -13.3% | — | — |
| May 7, 2026 | $-0.50 | $-0.46 | +8.0% | — | — |
| Feb 26, 2026 | $-0.43 | $-0.49 | -13.5% | — | — |
| Nov 6, 2025 | $-0.40 | $-0.39 | +2.5% | — | — |
| Aug 7, 2025 | $-0.42 | $-0.34 | +19.0% | — | — |
| May 8, 2025 | $-0.45 | $-0.43 | +4.4% | — | — |
| Mar 3, 2025 | $-0.39 | $-0.42 | -7.7% | — | — |
| Nov 7, 2024 | $-0.37 | $-0.36 | +2.7% | — | — |
| Aug 8, 2024 | $-0.36 | $-0.34 | +5.6% | — | — |
| May 9, 2024 | $-0.39 | $-0.33 | +15.4% | — | — |
| Feb 22, 2024 | $-0.44 | $-0.47 | -6.8% | $2M | — |
| Nov 9, 2023 | $-0.40 | $-0.41 | -2.5% | — | — |
EWTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Grant | 65,000 | $43.56 |
| Aug 17, 2026 | MOORE JOHN Rofficer: General Counsel | Grant | 65,000 | $43.56 |
| Aug 17, 2026 | Nofi Michaelofficer: Chief Financial Officer | Grant | 48,750 | $43.56 |
| Aug 17, 2026 | Derakhshan Behradofficer: Chief Business Officer | Grant | 100,000 | $43.56 |
| Aug 17, 2026 | Donovan Joanne M.officer: CMO | Grant | 65,000 | $43.56 |
| Aug 14, 2026 | KOCH KEVINdirector, officer: President and CEO | Grant | 100,000 | — |
| Aug 14, 2026 | KOCH KEVINdirector, officer: President and CEO | Grant | 200,000 | $43.56 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,839 | $43.78 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,779 | $43.71 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 104 | $44.43 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 800 | $44.52 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Sell | 2,919 | $43.41 |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Grant | 32,500 | — |
| Aug 14, 2026 | Donovan Joanne M.officer: CMO | Grant | 65,000 | — |
| Aug 14, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Option | 5,781 | — |
Source: EWTX SEC Form 4 filings, latest Aug 17, 2026. For informational purposes only — not investment advice.
See the full EWTX insider & 13F page →Edgewise Therapeutics, Inc. company profile
Overview
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.
Business
Edgewise Therapeutics operates in the biotechnology sector, specifically focusing on developing treatments for rare musculoskeletal diseases. The company's approach centers on creating small molecule drugs that can be taken orally, which represents a significant advantage over many current treatments for muscle diseases that require injections or infusions. The company's lead product candidate is EDG-5506, an orally administered small molecule drug designed to address the root cause of dystrophinopathies. Dystrophinopathies are a group of genetic muscle disorders caused by mutations in the dystrophin gene, which leads to progressive muscle weakness and degeneration. The two main conditions in this category are Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). DMD is particularly severe, typically affecting young boys and leading to wheelchair dependence by adolescence and shortened life expectancy. EDG-5506 has completed Phase 1 clinical trials, which primarily test for safety and determine appropriate dosing ranges. The drug is designed to work by targeting key muscle proteins and modulators that are disrupted in these genetic conditions. Beyond their lead candidate, Edgewise is developing a broader pipeline of precision medicine treatments that target various muscle proteins involved in genetically defined muscle disorders. The biotechnology industry in which Edgewise operates is characterized by high research and development costs, long development timelines typically spanning 10-15 years, and significant regulatory hurdles. Companies in this space often operate without revenue for many years while their drug candidates progress through clinical trials, relying on investor funding and partnerships to sustain operations.
Revenue model
As a clinical-stage biotechnology company, Edgewise currently generates no revenue from product sales, as evidenced by zero revenue across all reported quarters. The company's business model is built around developing drug candidates through clinical trials with the eventual goal of gaining regulatory approval and commercializing treatments for rare muscle diseases. The company's future revenue model will likely depend on several potential streams: direct product sales once drugs receive regulatory approval, licensing agreements with larger pharmaceutical companies, and potential milestone payments from development partnerships. Given that Edgewise focuses on rare diseases, their eventual commercial strategy may involve premium pricing due to the small patient populations and lack of existing treatment alternatives. Currently, the company funds its operations through equity financing from investors. The biotechnology sector requires substantial upfront investment with uncertain returns, as drug development has high failure rates and lengthy approval processes. Companies like Edgewise typically experience significant cash burn during development phases, with expenses primarily going toward clinical trials, research and development, regulatory affairs, and general corporate operations. Several factors could impact Edgewise's future margins and commercial success. Positive clinical trial results would likely increase the company's valuation and attract partnership opportunities with larger pharmaceutical companies that have established commercial infrastructure. Conversely, negative trial results or regulatory setbacks could significantly impact funding and development timelines. The competitive landscape for muscle disease treatments, regulatory approval processes, and the company's ability to demonstrate meaningful clinical benefits will all influence their eventual commercial success and pricing power.
Competitive moat
Edgewise Therapeutics operates in a specialized niche with limited competition, which provides some defensive characteristics but also highlights the inherent risks of biotechnology investing. The company's potential moat lies in their precision medicine approach to rare muscle diseases and their specific expertise in targeting muscle proteins and modulators. The rare disease focus provides certain advantages: smaller patient populations mean less competition from large pharmaceutical companies initially, and successful treatments can command premium pricing due to limited alternatives. Additionally, regulatory pathways for rare diseases often include incentives such as orphan drug designations, which can provide market exclusivity periods and development support. However, Edgewise's moat is currently theoretical rather than established. The company has no approved products, no revenue, and their lead candidate has only completed Phase 1 trials. Their competitive position depends entirely on successfully advancing EDG-5506 through remaining clinical phases and demonstrating superior efficacy compared to existing treatments or competing development programs. Potential disruption could come from several sources: larger pharmaceutical companies with greater resources developing competing treatments, alternative therapeutic approaches such as gene therapy or cell therapy gaining traction in muscle diseases, or other biotechnology companies achieving faster development timelines. The muscle disease treatment landscape is evolving rapidly, with various companies pursuing different therapeutic modalities including antisense oligonucleotides, gene therapy, and other small molecule approaches. The strength of any eventual moat will depend on clinical trial outcomes, the degree of efficacy demonstrated, safety profile, and the company's ability to establish intellectual property protection around their discoveries. Until clinical validation is achieved, the company's competitive position remains highly speculative.
Risks & safety
Edgewise presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong balance sheet metrics but significant execution risks. • Cash position and burn rate: The company maintains $49.9 million in cash and short-term investments as of Q1 2025, down from $86.1 million at the end of 2022. With quarterly operating cash flow burn of approximately $38 million in Q1 2025, the current cash position provides roughly 3-4 quarters of runway at current spending levels. • Debt and solvency: Excellent debt metrics with debt-to-equity ratio of only 1.1% and current ratio of 21.0, indicating strong short-term liquidity and minimal financial leverage risk. • Valuation considerations: Trading at 4.9x book value with negative earnings and EBITDA making traditional valuation metrics less meaningful. The Graham net-net ratio of 4.3 suggests the stock trades above conservative asset-based valuations. • Other considerations: No revenue generation creates dependency on continued equity financing or partnerships. The company's value is entirely dependent on clinical trial success, regulatory approval, and eventual commercialization - all highly uncertain outcomes with significant binary risk characteristics.
Recent development
Based on the available financial data, Edgewise has been primarily focused on advancing their lead candidate EDG-5506 through clinical development. The company completed Phase 1 clinical trials for their dystrophinopathy treatment, representing a significant milestone in demonstrating initial safety and establishing dosing parameters for the oral small molecule therapy. The financial progression shows increasing research and development expenditures, with annual net losses growing from $67.6 million in 2022 to $133.8 million in 2024, indicating accelerated investment in clinical development activities. This spending pattern is typical for biotechnology companies advancing through clinical stages, as later-phase trials require larger patient populations and more extensive monitoring. The company has maintained a strong balance sheet throughout this development period, though cash reserves have declined from $352 million at the end of 2022 to approximately $50 million by Q1 2025. This cash consumption reflects the substantial costs associated with clinical trial execution, regulatory preparation, and building the infrastructure necessary to support potential commercialization. Without access to recent earnings call transcripts, specific strategic initiatives and pipeline developments beyond the core EDG-5506 program cannot be detailed. However, the consistent focus on precision medicine approaches for genetically defined muscle disorders appears to remain the company's primary strategic direction, with the dystrophinopathy program serving as the lead indication for their platform approach.
EWTX company profile · for informational purposes only — not investment advice.
Track EWTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free